Clinical trials: Kidney Failure,Chronic
Chronic Kidney Disease, Hyperphosphatemia
A Study to Assess the Pharmacokinetics of Lanthanum Carbonate, Investigate and Compare the Efficacy, Safety and Tolerability of Lanthanum Carbonate With Calcium Carbonate in Hyperphosphataemic Children and Adolescents With Chronic Kidney Disease on Dialysis
The purpose of this study is to summarize the percentage of participants achieving age-specific Kidney Disease Outcomes Quality Initiative (KDOQI) targets for serum phosphorus in hyperphosphatemic children and adolescents with…
- Trial name
- NCT01696279
- Testing
- Lanthanum Carbonate, Calcium Carbonate
- Where
- 22 sites in Argentina, Chile and 7 more
- Volunteers
- 63 people
- Sponsor
- Shire
Type 2 Diabetes Mellitus, Chronic Kidney Disease
Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome
Among adult individuals with type 2 diabetes mellitus and at risk for heart failure with impaired relaxation of the heart mildly reduced kidney filtration function (Type 4 cardiorenal syndrome) this trial will evaluate the…
- Conditions
- Type 2 Diabetes Mellitus, Chronic Kidney Disease, Left Ventricular Diastolic Dysfunction
- Trial name
- NCT02251431
- Testing
- BYDUREON
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Baylor Research Institute
End-Stage Renal Disease, End-Stage Kidney Disease
Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)
The purpose of this study is to evaluate the efficacy and safety of two different doses of MK-2060 (a monoclonal antibody against Factor XI) in end stage renal disease (ESRD) participants receiving hemodialysis via an…
- Conditions
- End-Stage Renal Disease, End-Stage Kidney Disease, Kidney Failure, Chronic
- Trial name
- NCT05027074
- Testing
- MK-2060
- Where
- 120 sites in United States, Argentina and 13 more
- Volunteers
- 506 people
- Sponsor
- Merck Sharp & Dohme LLC
Anemia Associated With End Stage Renal Disease
Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants
The purpose of this study is to assess the safety and effectiveness of roxadustat dosing regimens among hemodialysis participants converted from erythropoiesis stimulating agent (ESA) therapy or who are ESA-naïve.
- Trial name
- ASPEN (NCT04484857)
- Testing
- Roxadustat
- Where
- 26 sites in United States
- Volunteers
- 283 people
- Sponsor
- Kyntra Bio
Kidney Failure, Chronic
Pharmacokinetics of Sublingual Versus Oral Tacrolimus in Patients Awaiting Kidney Transplantation
Tacrolimus (Prograf) belongs to a class of medications known as the calcineurin inhibitors. It is a maintenance drug that is used to prevent rejection in kidney, liver, and heart transplant recipients.
- Trial name
- NCT00629122
- Testing
- Tacrolimus (Arm B), Clotrimazole Troche, Tacrolimus (Arm A)
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Weill Medical College of Cornell University
Kidney Failure, Chronic
Observational Study to Evaluate the Time to Achieving the Maintenance Dose of Zemplar® (Paricalcitol Injection) in the Treatment of Patients Suffering From End-stage Renal Disease and Severe Over-reactivity of the Parathyroid Glands
This observational study will evaluate the clinical benefit of Zemplar (paricalcitol injection) in daily routine practice in end-stage renal disease patients with severe over-reactivity of parathyroid glands.
- Trial name
- NCT01273597
- Where
- 11 sites in Hungary
- Volunteers
- 60 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Chronic Kidney Diseases, Type 2 Diabetes
Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management
The goal of this study is to test whether a dipeptidyl peptidase-4 inhibitor, compared with a sulfonylurea, improves time in normal blood glucose range and reduces blood glucose variability.
- Trial name
- CANDY-CANE (NCT02608177)
- Testing
- Linagliptin, Glipizide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Washington
Chronic Kidney Disease
Empowering Patients on Choices for Renal Replacement Therapy (Aim 2)
Empowering Patients On Choices for Renal Replacement Therapy (EPOCH-RRT) study seeks to identify factors that matter the most to patients with kidney disease and study how they are impacted by different types of dialysis.
- Trial name
- EPOCH-RRT (NCT02440659)
- Where
- United States
- Volunteers
- 2,946 people, healthy volunteers welcome
- Sponsor
- Arbor Research Collaborative for Health
Anemia
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis
The purpose of this study is to evaluate whether hemodialysis patients on peginesatide can be converted to epoetin alfa by using a predefined conversion table while achieving a stable hemoglobin.
- Trial name
- NCT01737879
- Testing
- Peginesatide, Epoetin alfa
- Where
- 23 sites in United States
- Volunteers
- 41 people
- Sponsor
- Amgen
End Stage Renal Disease
Ultrafiltration Profiling and Outcomes Among Individuals on Maintenance Hemodialysis
The rate of fluid removal (ultrafiltration, UF) during hemodialysis (HD) may contribute to cardiovascular morbidity and mortality among individuals receiving maintenance HD.
- Trial name
- NCT03301740
- Testing
- UF profiling during HD, Conventional HD
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- University of North Carolina, Chapel Hill
Critical Illness, Chronic Disease
Improving Communication About Serious Illness
The purpose of this study is to improve care delivered to patients with serious illness by enhancing communication among patients, families, and clinicians in the outpatient setting.
- Conditions
- Critical Illness, Chronic Disease, Terminal Care, Palliative Care
- Trial name
- ICSI (NCT01933789)
- Testing
- Communication Feedback Form for Patients with Serious Illness
- Where
- 6 sites in United States
- Volunteers
- 817 people
- Sponsor
- University of Washington
End-Stage Renal Disease, Hemodialysis
Pharmacokinetics And Dialysability Of CP-690,550 In Subjects With End-Stage Renal Disease
There were 2 study periods in this study. In the Period 1, CP-690,550 was to be administered approximately 1 to 2 hours following hemodialysis.
- Trial name
- NCT01710020
- Testing
- CP-690,550
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Pfizer
Diabetes, End Stage Renal Disease
Hyperglycemia in Renal Transplantation
Based on multiple prior studies, kidney transplant recipients with diabetes are at higher risk for poor initial graft function after transplant.
- Trial name
- HiRT (NCT01643382)
- Testing
- Insulin, Insulin, Asp(B28)-
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of California, San Francisco
Chronic Kidney Disease, Hyperphosphatemia
A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia
This is a phase III multi-centre study in three periods: the first period is a phosphate binder washout for 4 weeks, the second period is an open-label, randomised, parallel group, flexible dose, the third period is a…
- Trial name
- NCT00416520
- Testing
- MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE®), Another phosphate binder (Sevelamer)
- Where
- 68 sites in Australia, Austria and 9 more
- Volunteers
- 336 people
- Sponsor
- Tanabe Pharma Corporation
Kidney Failure, Chronic
Clinical Study of Asahi ViE Dialyzer in Canada
The purpose of the study is to obtain performance data on the Asahi ViE-21 dialyzer (ViE-21) .
- Trial name
- AVID (NCT02292212)
- Testing
- ViE-21
- Volunteers
- 17 people
- Sponsor
- Asahi Kasei Medical Co., Ltd.
End Stage Renal Disease (ESRD)
Delivery of Soluble Ferric Pyrophosphate (SFP) Via the Dialysate to Maintain Iron Balance in Hemodialysis Patients
In maintenance hemodialysis patients, regular administration of parenteral iron by addition of soluble ferric pyrophosphate (SFP) to the dialysate, when compared to conventional dialysate, is effective in preventing the…
- Trial name
- NCT00604565
- Testing
- soluble ferric pyrophosphate (SFP)
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Charles Drew University of Medicine and Science
Radiographic Contrast Agent Nephropathy
Contrast Media Reduction and Removal in Patients With Chronic Kidney Disease (CKD) (PRESERV)
The purpose of this clinical trial is to demonstrate the efficacy and safety of the Osprey Medical CINCOR™ Contrast Removal System.
- Trial name
- NCT01168024
- Testing
- CINCOR™ System and contrast conservation unit (CCS-1), Standard of Care plus peri-procedural hydration
- Where
- 21 sites in United States, Germany
- Volunteers
- 16 people
- Sponsor
- Osprey Medical, Inc
Kidney Failure, Chronic, Cardiovascular Disease
Hydroxychloroquine in Cardiovascular Disease in Patients With Chronic Kidney Disease: A Proof of Concept Study
Presence of multiple traditional and nontraditional risk factors of atherosclerosis and cardiovascular disease (CVD) including inflammation in patients with chronic kidney disease (CKD) contribute to high CVD morbidity and…
- Conditions
- Kidney Failure, Chronic, Cardiovascular Disease, Arteriosclerosis
- Trial name
- NCT01537315
- Testing
- Hydroxychloroquine
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- University of Arkansas
Chronic Kidney Diseases
Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)
This Phase 3, randomized, Double-blind, placebo-controlled, 2-arm, parallel-group, multicenter study with randomized withdrawal will evaluate the efficacy, safety, and durability of KBP-5074 in adult participants who have stage…
- Trial name
- Clarion-CKD (NCT04968184)
- Testing
- KBP-5074
- Where
- 215 sites in United States, Australia and 20 more
- Volunteers
- 666 people
- Sponsor
- Novo Nordisk A/S
Kidney Failure, Chronic
A Study in Participants With End-Stage Renal Disease
The purpose of this trial is to explore the effect of LY2127399 on those antibodies that are a barrier to kidney transplant. Transplantation is currently the definitive treatment for End-Stage Renal Disease (ESRD), providing…
- Trial name
- NCT01200290
- Testing
- LY2127399
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Eli Lilly and Company